Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Lumipulse proved successful in a clinical trial. Before earning FDA clearance, a clinical trial tested the blood samples of 499 cognitively impaired adults to evaluate them for Alzheimer’s disease.

The FDA has cleared Lumipulse, the first-ever blood test for early Alzheimer's detection, reducing the need for costly and invasive procedures.

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The FDA issued clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio to Fujirebio Diagnostics, Inc.

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of cognitive decline.

The US Food and Drug Administration (FDA) has granted 510 (k) clearance to the first blood test to aid in diagnosing Alzheimer’s disease (AD). The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma ...

The FDA has granted 510 (k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ -Amyloid 1-42 Plasma ...

The FDA has approved the first blood test to detect signs of Alzheimer’s disease, marking a major step toward easier diagnosis. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, making the test the first to get signoff to aid in the early detection of ...